|Mr. Armando Anido M.B.A., MBA||Chairman & CEO||911.86k||N/A||1958|
|Ms. Terri B. Sebree||Pres||690.42k||N/A||1958|
|Mr. James E. Fickenscher||CFO, VP of Corp. Devel. & Treasurer||556.9k||N/A||1964|
|Mr. William C. Roberts||VP of Investor Relations & Corp. Communications||N/A||N/A||1969|
|Ms. Suzanne M. Hanlon||Sec., VP & Gen. Counsel||N/A||N/A||1957|
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Zynerba Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 8.